Immunotech Biopharm's (HKG:6978) loss attributable to owners in 2024 narrowed year on year to 186.9 million yuan or 0.36 per share from 334.8 million yuan or 0.65 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.
The biopharmaceutical company's other income surged 220% to 33.8 million yuan from 10.5 million yuan in the previous year.
No dividend was recommended for the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.